Literature DB >> 18205042

25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture.

Xinjian Peng1, Michael Hawthorne, Avani Vaishnav, René St-Arnaud, Rajendra G Mehta.   

Abstract

Despite the role of vitamin D(3) endocrine system in prevention of mammary gland transformation in animal models, use of 1,25(OH)(2)D(3 )in clinical settings is precluded due to its toxicity in vivo. Therefore much effort has been placed in developing relatively non-toxic vitamin D analogs. Recently, with the discovery of the expression of 25-hydroxy vitamin D(3) 1alpha-hydroxylase (CYP27B1) in multiple extrarenal organs, the functional role of prohormone, 25-hydroxyvitamin D(3) [25(OH)D(3)], has been redefined. Since 25(OH)D(3) does not cause hypercalcemia and maintains relative high concentration in serum, it is possible that the prohormone can be converted to active hormone in mammary epithelial cells to provide chemopreventive effects. In the present study, we evaluated its functional significance using mouse mammary organ culture (MMOC) system. We first showed that 25(OH)D(3) 1alpha-hydroxylase is extensively expressed in mammary ductal epithelial cells at both protein and mRNA levels, which is a prerequisite for 25(OH)D(3) to function in an autocrine/paracrine manner. However, we also observed that clotrimazol (1alpha-hydroxylase inhibitor) enhanced 25(OH)D(3) -induced CYP24 expression in breast cancer cells. In mammary glands derived from 1alpha-hydroxylase knockout mice, 25(OH)D(3) treatment in organ culture significantly induced CYP24 expression, indicating a potential direct effect of 25(OH)D(3). In MMOC, 100-250 nM 25(OH)D(3) suppressed both ovarian hormone-dependent and -independent mammary precancerous lesions (induced by DMBA) by more than 50%, while the active hormone 1,25(OH)(2)D(3) (positive control) at 100 nM suppressed alveolar lesions by more than 80%. The inactive vitamin D(3) (negative control) at 100 nM suppressed alveolar lesions by only 20% (P>0.05). We found that 25(OH)D(3) inhibits DMBA-induced mammary alveolar lesions (MAL) in a stage-specific manner: 25(OH)D(3) mainly inhibits the promotion stage of lesion formation. We conclude that 25(OH)D(3) could serve as a non-toxic natural chemopreventive agent for further development for breast cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205042      PMCID: PMC2695979          DOI: 10.1007/s10549-008-9900-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  41 in total

1.  Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.

Authors:  R G Mehta; R M Moriarty; R R Mehta; R Penmasta; G Lazzaro; A Constantinou; L Guo
Journal:  J Natl Cancer Inst       Date:  1997-02-05       Impact factor: 13.506

2.  Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets.

Authors:  O Dardenne; J Prud'homme; A Arabian; F H Glorieux; R St-Arnaud
Journal:  Endocrinology       Date:  2001-07       Impact factor: 4.736

3.  An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3.

Authors:  A Nykjaer; D Dragun; D Walther; H Vorum; C Jacobsen; J Herz; F Melsen; E I Christensen; T E Willnow
Journal:  Cell       Date:  1999-02-19       Impact factor: 41.582

4.  1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.

Authors:  S Swami; A V Krishnan; D Feldman
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

Review 5.  Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety.

Authors:  R Vieth
Journal:  Am J Clin Nutr       Date:  1999-05       Impact factor: 7.045

6.  Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1.

Authors:  G K Fu; D Lin; M Y Zhang; D D Bikle; C H Shackleton; W L Miller; A A Portale
Journal:  Mol Endocrinol       Date:  1997-12

7.  Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5).

Authors:  R Mehta; M Hawthorne; L Uselding; D Albinescu; R Moriarty; K Christov; R Mehta
Journal:  J Natl Cancer Inst       Date:  2000-11-15       Impact factor: 13.506

Review 8.  Vitamin D, calcium and prevention of breast cancer: a review.

Authors:  M Lipkin; H L Newmark
Journal:  J Am Coll Nutr       Date:  1999-10       Impact factor: 3.169

Review 9.  Beneficial effects of sun exposure on cancer mortality.

Authors:  H G Ainsleigh
Journal:  Prev Med       Date:  1993-01       Impact factor: 4.018

10.  Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.

Authors:  R J Skowronski; D M Peehl; D Feldman
Journal:  Endocrinology       Date:  1995-01       Impact factor: 4.736

View more
  19 in total

Review 1.  Vitamin D metabolism and action in the prostate: implications for health and disease.

Authors:  Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

Review 2.  The relationship between vitamin D and breast cancer incidence and natural history.

Authors:  Qamar J Khan; Bruce F Kimler; Carol J Fabian
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

Review 3.  Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: importance of mammary CYP27B1 for treatment and prevention.

Authors:  Aruna V Krishnan; Srilatha Swami; David Feldman
Journal:  J Steroid Biochem Mol Biol       Date:  2012-08-23       Impact factor: 4.292

Review 4.  Cellular and molecular effects of vitamin D on carcinogenesis.

Authors:  JoEllen Welsh
Journal:  Arch Biochem Biophys       Date:  2011-11-09       Impact factor: 4.013

5.  Dietary vitamin D₃ and 1,25-dihydroxyvitamin D₃ (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer.

Authors:  Srilatha Swami; Aruna V Krishnan; Jennifer Y Wang; Kristin Jensen; Ronald Horst; Megan A Albertelli; David Feldman
Journal:  Endocrinology       Date:  2012-03-27       Impact factor: 4.736

Review 6.  Function of the vitamin D endocrine system in mammary gland and breast cancer.

Authors:  JoEllen Welsh
Journal:  Mol Cell Endocrinol       Date:  2017-06-01       Impact factor: 4.102

7.  1,25-Dihydroxyvitamin D Regulation of Glutamine Synthetase and Glutamine Metabolism in Human Mammary Epithelial Cells.

Authors:  Sarah Beaudin; JoEllen Welsh
Journal:  Endocrinology       Date:  2017-12-01       Impact factor: 4.736

Review 8.  Vitamin D as a Potential Preventive Agent For Young Women's Breast Cancer.

Authors:  Sarah M Bernhardt; Virginia F Borges; Pepper Schedin
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09

9.  Vitamin d: are we ready to supplement for breast cancer prevention and treatment?

Authors:  Katherine D Crew
Journal:  ISRN Oncol       Date:  2013-02-26

10.  Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture.

Authors:  Cintia Milani; Maria Lucia Hirata Katayama; Eduardo Carneiro de Lyra; JoEllen Welsh; Laura Tojeiro Campos; M Mitzi Brentani; Maria do Socorro Maciel; Rosimeire Aparecida Roela; Paulo Roberto del Valle; João Carlos Guedes Sampaio Góes; Suely Nonogaki; Rodrigo Esaki Tamura; Maria Aparecida Azevedo Koike Folgueira
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.